Zhongyuan Union Cell & Gene Engineering Corp announced last week its plan to buy U.S.-based gene centric life sciences company OriGene Technologies Inc by acquiring the 100 percent stake of a Shanghai-based investment company.
Shanghai-listed Zhongyuan Union primarily engages in the detection and storage of stem cell sources in China, with its business also covering areas such as gene detection, gene testing and clinical diagnosis.
Wholly owned by Shanghai Aoyuan Investment Management Co, OriGene was founded in 1996 in the U.S. as a research tool company focused on the creation of the largest commercial collection of full-length human complementary DNAs in a standard expression vector.
(Source: Global Times)
A single purchase
